The Impact of GlowCaps Connect™ and Its Services on Hypertension Medication Adherence
NCT ID: NCT00985452
Last Updated: 2012-10-10
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
139 participants
INTERVENTIONAL
2009-08-31
2010-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Group 1
* The GlowCap bottle provided for subjects in this group will passively track medication adherence over the course of the study
* The pill cap will collect data, but will not provide any visual or auditory alerts
* An Ethernet Gateway connector will collect adherence data from the pill bottle cap via a local wireless network. This data will be sent out of subject's home through the internet.
Group 2
* Subjects in this group will be given daily visual, auditory, and phone call reminders to take their medication via the GlowCap system if they fail to take their hypertension medication at the scheduled dose time
* An Ethernet Gateway connector will collect adherence data from the pill bottle cap via a local wireless network. This data will be sent out of subject's home through the internet.
* Subjects will receive Weekly and Monthly Progress Reports by email and mail, respectively. Reports will include information about medication adherence and target goals. If a subject does not opt-out, Monthly Progress Reports will also be sent to the subject's primary care physician (PCP)
* If the subject chooses, a friend or family member will receive a Weekly Progress Report by email
* If the subject chooses, he/she will receive prompts (via automated telephone call twice a month) to refill his/her prescription
* Subjects demonstrating consistent low adherence to medication will receive additional support in the form of calls from Vitality reminding them to take the medication.
Group 3
* Subjects in this group will be given daily visual, auditory, and phone call reminders to take their medication via the GlowCap system if they fail to take their hypertension medication at the scheduled dose time
* An Ethernet Gateway connector will collect adherence data from the pill bottle cap via a local wireless network. This data will be sent out of subject's home through the internet.
* Subjects will receive Weekly and Monthly Progress Reports by email and mail, respectively. Reports will include information about medication adherence and target goals. If a subject does not opt-out, Monthly Progress Reports will also be sent to the subject's primary care physician (PCP)
* If the subject chooses, a friend or family member will receive a Weekly Progress Report by email
* Subjects will receive financial incentives in the form of a check for meeting a target adherence goal of 80% adherence over each month. The check will be mailed to them at the end of the study.
* If the subjects chooses, he/she will receive prompts (via automated telephone call twice a month) to refill his/her prescription
* Subjects demonstrating consistent low adherence to medication will receive additional support in the form of calls from Vitality reminding them to take the medication and may receive increased financial incentives to meet their target.
Study subjects will attend two study visits, one at the beginning and one at the end of the 6 month period. At these visits they will have their blood pressure recorded and will be asked to complete a survey.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
FACTORIAL
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Group 2: Intervention
Subjects in Group two will received an activated GlowCaps system, which will remind them to take their medication.
GlowCaps Connect system
The GlowCaps Connect system is an electronic medication reminder system, which provides reminders to help people to remember to take their medication.
Group 3: Intervention/financial incentive
Subjects in group 3 will receive an activated GlowCaps system, which will provide them with reminders to take their medication, Subjects in group 3 will also receive an additional financial incentive, the amount will be based on how often they remembered to take their medication during the 6-month study.
GlowCaps Connect system
The GlowCaps Connect system is an electronic medication reminder system, which provides reminders to help people to remember to take their medication.
Group 1: Control
Subjects in group one will receive a de-activated GlowCaps system, which will not provide the reminder service.
Glow cap system - deactivated
The Glow cap system - deactivated is an electronic medication system, which will track medication adherence.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
GlowCaps Connect system
The GlowCaps Connect system is an electronic medication reminder system, which provides reminders to help people to remember to take their medication.
Glow cap system - deactivated
The Glow cap system - deactivated is an electronic medication system, which will track medication adherence.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Diagnosis of hypertension
* Take a once a day medication for hypertension
* Internet access via broadband (not dial-up)
* Home router
* A private email account
* Fluency in English (spoken and written)
* Have a Primary Care Physician
Exclusion Criteria
* People with significant cognitive deficits will be excluded.
* People will be excluded if they take more than three medications a day for hypertension.
* People will be excluded if they take more than five medications in one day.
* People will be excluded if they have total color blindness.
* People will be excluded if they are both blind and deaf.
18 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Massachusetts General Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Joseph C. Kvedar
Director, Center for Connected Health
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Joseph C Kvedar, MD
Role: PRINCIPAL_INVESTIGATOR
Massachusetts General Hospital
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2009-P-000254/3;MGH
Identifier Type: -
Identifier Source: org_study_id